Guggenheim Capital’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.47M Buy
11,848
+11
+0.1% +$3.62K 0.03% 533
2025
Q4
$4.15M Sell
11,837
-3,524
-23% -$1.19M 0.03% 479
2025
Q3
$4.96M Sell
15,361
-1,498
-9% -$466K 0.04% 444
2025
Q2
$6.56M Sell
16,859
-1,303
-7% -$524K 0.05% 355
2025
Q1
$7.9M Sell
18,162
-831
-4% -$334K 0.07% 299
2024
Q4
$7.01M Sell
18,993
-1,353
-7% -$566K 0.06% 350
2024
Q3
$10.6M Sell
20,346
-3,103
-13% -$1.66M 0.07% 292
2024
Q2
$12.7M Buy
23,449
+1,662
+8% +$879K 0.09% 236
2024
Q1
$11.3M Buy
21,787
+7,859
+56% +$3.91M 0.08% 284
2023
Q4
$6.57M Sell
13,928
-846
-6% -$391K 0.05% 442
2023
Q3
$6.43M Buy
14,774
+7,220
+96% +$3.27M 0.06% 411
2023
Q2
$3.36M Buy
7,554
+17
+0.2% +$7.84K 0.03% 671
2023
Q1
$3.47M Buy
7,537
+744
+11% +$354K 0.03% 650
2022
Q4
$3.48M Buy
6,793
+920
+16% +$467K 0.03% 651
2022
Q3
$2.67M Sell
5,873
-5,703
-49% -$2.73M 0.02% 732
2022
Q2
$5.59M Sell
11,576
-7,278
-39% -$3.6M 0.04% 494
2022
Q1
$9.26M Sell
18,854
-829
-4% -$379K 0.06% 418
2021
Q4
$9.12M Sell
19,683
-2,148
-10% -$904K 0.05% 463
2021
Q3
$8.14M Sell
21,831
-2,771
-11% -$1.05M 0.05% 458
2021
Q2
$9.39M Sell
24,602
-2,573
-9% -$983K 0.06% 417
2021
Q1
$9.75M Buy
27,175
+3,789
+16% +$1.22M 0.06% 377
2020
Q4
$7.51M Buy
23,386
+5,223
+29% +$1.6M 0.05% 424
2020
Q3
$4.88M Buy
18,163
+3,671
+25% +$988K 0.04% 540
2020
Q2
$3.81M Buy
14,492
+5,135
+55% +$1.37M 0.03% 626
2020
Q1
$2.12M Sell
9,357
-7,342
-44% -$2M 0.02% 765
2019
Q4
$5.04M Sell
16,699
-4,247
-20% -$1.17M 0.04% 628
2019
Q3
$5.03M Sell
20,946
-2,839
-12% -$778K 0.04% 593
2019
Q2
$6.71M Sell
23,785
-467
-2% -$128K 0.05% 450
2019
Q1
$6.96M Sell
24,252
-10,876
-31% -$3.15M 0.06% 441
2018
Q4
$9.22M Buy
35,128
+5,322
+18% +$1.46M 0.08% 292
2018
Q3
$8.17M Sell
29,806
-3,024
-9% -$785K 0.05% 445
2018
Q2
$7.82M Sell
32,830
-177,920
-84% -$41.2M 0.05% 446
2018
Q1
$46.3M Sell
210,750
-12,234
-5% -$2.87M 0.11% 367
2017
Q4
$50.2M Sell
222,984
-142,707
-39% -$30.4M 0.12% 332
2017
Q3
$69.4M Buy
365,691
+2,161
+0.6% +$411K 0.16% 117
2017
Q2
$68.4M Sell
363,530
-2,748
-0.8% -$494K 0.18% 119
2017
Q1
$60.6M Buy
366,278
+8,517
+2% +$1.35M 0.16% 164
2016
Q4
$51.4M Buy
357,761
+7,286
+2% +$976K 0.15% 205
2016
Q3
$43.9M Sell
350,475
-4,590
-1% -$593K 0.14% 230
2016
Q2
$46.6M Buy
355,065
+15,708
+5% +$2.15M 0.15% 199
2016
Q1
$47.2M Sell
339,357
-52,554
-13% -$7.02M 0.15% 181
2015
Q4
$54.6M Buy
391,911
+13,152
+3% +$1.81M 0.16% 152
2015
Q3
$53M Sell
378,759
-70,176
-16% -$10.5M 0.16% 126
2015
Q2
$73.7M Sell
448,935
-8,674
-2% -$1.39M 0.18% 89
2015
Q1
$70.7M Sell
457,609
-28,462
-6% -$4.05M 0.17% 114
2014
Q4
$61.1M Sell
486,071
-170,947
-26% -$21.1M 0.15% 144
2014
Q3
$78.6M Sell
657,018
-8,571
-1% -$983K 0.19% 81
2014
Q2
$71.6M Buy
665,589
+110,523
+20% +$11.4M 0.18% 90
2014
Q1
$55.3M Buy
555,066
+44,435
+9% +$4.02M 0.16% 124
2013
Q4
$47.2M Buy
510,631
+101,720
+25% +$9.04M 0.14% 150
2013
Q3
$34.2M Buy
408,911
+74,424
+22% +$6.38M 0.12% 183
2013
Q2
$27.4M Buy
+334,487
New +$25M 0.12% 198

Other funds holding ELV

Guggenheim Capital's ELV Position: Q1 2026 in Review

Guggenheim Capital increased its Elevance Health (ELV) stake by 0.09% in Q1 2026, buying an estimated $3.62K and bringing the position to 11,848 shares worth $3.47M. The position accounts for 0.03% of the portfolio, ranked #533.

Guggenheim Capital first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $78.6M in Q3 2014. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Guggenheim Capital held 11,848 shares of Elevance Health worth $3.47M as of Q1 2026.
  • Guggenheim Capital bought 11 Elevance Health shares in Q1 2026, an estimated $3.62K.
  • Elevance Health made up 0.03% of Guggenheim Capital's portfolio in Q1 2026, its #533 holding.
  • Guggenheim Capital first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's Elevance Health position peaked at $78.6M in Q3 2014.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.